Alnylam Pharmaceuticals, Inc. (ALNY) Up 6.6% — Is Now When I Pull In?

  • ALNY rose 6.63% to $167.04 from $156.65 the previous trading day
  • Weiss Ratings assigns C (Hold)
  • Market cap is $20.98B

Alnylam Pharmaceuticals, Inc. (ALNY) is pushing higher this Friday, with shares last changing hands at $167.04 on the NASDAQ. That is a $10.39 gain from the prior close of $156.65. The advance gives the stock a firm footing after a punishing year. ALNY still trades roughly 65.2% below its 52-week high of $479.79, a level it reached on December 3, 2025. That leaves a wide gap between today's price and where the market valued this business less than a year ago, and buyers are starting to work into that gap.

Volume stands at approximately 739,968 shares so far in the session, compared with a 90-day average of about 2.10 million. With the regular session still open, turnover is tracking toward a fuller count as the day progresses.


Why Alnylam Pharmaceuticals, Inc. Price is Moving Higher

Today's rally is company-specific. It is driven by renewed investor attention to AMVUTTRA's long-term clinical evidence rather than any lift from the broader tape. In the prior session on November 12, the S&P 500 and Nasdaq each fell 0.4%, and large-cap Health Care names are mostly flat to lower today. Merck & Co., Inc. (MRK) is off 0.29% and Pfizer Inc. (PFE) is down 0.42%, which makes ALNY's 6.63% gain stand out sharply against its peers.

The fuel is the five-year HELIOS-B data Alnylam presented at the American Heart Association meeting on November 9. Patients treated continuously with AMVUTTRA showed a 41% lower risk of death plus repeat cardiovascular events across the full study population. That comparison was against patients who started treatment roughly three years later. In the subgroup not taking tafamidis at baseline, the risk reduction widened to 48%. Those figures strengthen the case for earlier AMVUTTRA use in ATTR cardiomyopathy, which is the market that matters most to Alnylam's growth trajectory. Wall Street support followed quickly. On November 11, H.C. Wainwright reiterated its Buy rating and $455 price target, which implies substantial upside from current levels.

The fundamental backdrop gives the clinical story real weight. Alnylam's Q3 report on October 29 showed revenue of $1.458 billion against a $1.43 billion consensus, up 17% year over year. Adjusted EPS came in at $16.26 versus a $1.66 estimate, a figure lifted by a roughly $1.9 billion noncash tax benefit. AMVUTTRA sales climbed 65% year over year to $1.13 billion, just shy of the $1.15 billion estimate. Management reiterated full-year TTR revenue guidance of $4.2 billion to $4.5 billion. Durable long-term outcomes data now sit on top of a franchise already growing at that pace, and investors are paying attention.


What is the Alnylam Pharmaceuticals, Inc. Rating - Should I Buy?

Weiss Ratings assigns ALNY a C rating. Current recommendation is Hold. The rating captures a company whose operating fundamentals have sharply outpaced its stock performance. That disconnect is exactly what makes the name worth watching for investors hunting for opportunity in Health Care.

The business itself is rated strongly. The Excellent rating on the Growth Index is backed by 16.74% revenue growth and a 65% year-over-year jump in AMVUTTRA sales. Those numbers mark a commercial-stage RNAi company whose lead cardiology franchise is scaling rapidly. The Excellent Solvency Index rating shows a balance sheet capable of funding continued launches and pipeline work without strain. The Good rating on the Efficiency Index reflects a 141.97% ROE and a 54.34% profit margin. Those are striking figures for a biotech that only recently crossed into consistent profitability. The rating stops short of Excellent largely because the roughly $1.9 billion noncash tax benefit inflates both measures beyond what the core operations alone would produce. At a forward P/E of 7.91, the market is assigning a modest multiple to a company growing this fast.

Where the picture becomes more nuanced is in the market-facing dimensions. ALNY is rated Weak on both the Total Return Index and the Volatility Index. One fact explains both ratings: shares sit about 65.2% below their December 2025 peak. That drawdown has erased a large share of holders' gains, and it has come with sharp swings along the way. Even today's welcome 6.63% jump on the HELIOS-B data illustrates why the Volatility Index is not rated higher, since clinical readouts can move this stock by high single digits in a session. These two ratings hold the overall grade at C rather than lifting it into Buy territory.

Within the Health Care sector, Alnylam sits alongside Merck & Co., Inc. (MRK, C), Gilead Sciences, Inc. (GILD, C), and Danaher Corporation (DHR, C). It trails Pfizer Inc. (PFE, C+) and Regeneron Pharmaceuticals, Inc. (REGN, C+) by one notch. Among that group, few can match Alnylam's current growth rate. That leaves room for an upgrade if the stock's return profile begins to catch up with its fundamentals.


About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (ALNY) is a Health Care company that pioneered RNA interference (RNAi) therapeutics as a commercial drug class. Headquartered in Cambridge, Massachusetts, Alnylam develops medicines that silence the specific genes driving disease. This approach targets the root cause of a condition upstream rather than treating its downstream symptoms.

The commercial portfolio centers on transthyretin-mediated (ATTR) amyloidosis. AMVUTTRA (vutrisiran) has become the company's flagship product, treating both the polyneuropathy of hereditary ATTR amyloidosis and ATTR cardiomyopathy with quarterly subcutaneous dosing. ONPATTRO (patisiran), the first RNAi therapeutic ever approved, also addresses hereditary ATTR polyneuropathy. Beyond amyloidosis, GIVLAARI (givosiran) treats acute hepatic porphyria and OXLUMO (lumasiran) treats primary hyperoxaluria type 1. Inclisiran, a cholesterol-lowering RNAi therapy developed with Alnylam's technology, is commercialized by Novartis as Leqvio, which gives Alnylam a royalty stream in cardiovascular disease.

Alnylam's competitive advantage rests on two decades of platform expertise in RNAi chemistry and delivery, particularly to the liver. That foundation supports a deep pipeline that extends into cardiometabolic, neurological, and other disease areas. The company's long-term clinical datasets set it apart in the ATTR cardiomyopathy market, where it competes against stabilizer therapies such as tafamidis. HELIOS-B is the clearest example. Its five-year outcomes data give physicians a compelling rationale for early intervention.


Investor Outlook

Alnylam Pharmaceuticals, Inc. (ALNY) carries a Weiss Rating of C (Hold). Today's move shows that strong clinical evidence can quickly bring buyers back to a stock trading far below its highs. Investors should watch whether AMVUTTRA's quarterly sales keep tracking toward the $4.2 billion to $4.5 billion full-year TTR guidance, and whether the HELIOS-B outcomes data translate into earlier prescribing. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.

--

This Weiss Instant News Alert was compiled by narrative data technology, our proprietary ratings models and analysis by Weiss Ratings with the intent of providing our readers with the fastest research and independent coverage. Weiss Instant News Alerts have been reviewed by a member of our editorial staff before publication. Please send any questions or comments about this story to [email protected]
Top Tech Stocks
See All »
B
AAPL NASDAQ $352.45
B
MSFT NASDAQ $508.29
B
NVDA NASDAQ $150.96
Top Consumer Staple Stocks
See All »
B
WMT NASDAQ $127.36
B
Top Financial Stocks
See All »
B
A
JPM NYSE $324.11
B
V NYSE $415.22
Top Energy Stocks
See All »
B
CVX NYSE $205.88
B
COP NYSE $134.40
Top Health Care Stocks
See All »
B
LLY NYSE $1,382.75
B
JNJ NYSE $272.70
B
ABBV NYSE $286.01
Top Real Estate Stocks
See All »
B
PLD NYSE $125.22